The Clozapine & LAI Virtual Forum is an all-new, peer-to-peer, interactive dialogue between psychiatrists, nurse practitioners, and other prescribing clinicians. It is informal, no registration required — just join our Zoom call and share your challenges and questions on the month's trending topic around either clozapine or LAIs.

**TODAY’S TOPIC:**

*Update on the Long-Acting Injectable Antipsychotic Medications*
MODERATORS

Robert Cotes, MD
SMI Adviser Physician Expert; Emory University

Dr. Robert Cotes, MD, is an Associate Professor at Emory University School of Medicine in the Department of Psychiatry and Behavioral Sciences. He has interest in clozapine, characterizing persistent symptoms of schizophrenia, understanding cardiometabolic side effects of antipsychotic medications, and first episode psychosis.

Donna Rolin, PhD, APRN
SMI Adviser Nursing Expert; University of Texas, Austin

Dr. Donna Rolin is Clinical Associate Professor and the Director of the Psychiatric Mental Health Nurse Practitioner program at the University of Texas with 23 years of experience in psychiatric nursing, including inpatient, community, forensic, and older adult settings.

Megan Ehret, PharmD, MS, BCPP
SMI Adviser Pharmacy Consultant, University of Maryland

Dr. Megan Ehret is a Professor at University of Maryland School of Pharmacy in the Department of Practice, Sciences, and Health Outcomes Research and is Co-Director of the Mental Health Program. She is a Past-President of the American Association of Psychiatric Pharmacists. Her current interests include psychotropic medication adherence and the incorporation of the psychiatric pharmacist in practice.
Discussion Questions for Virtual Forum:
Update on the Long-Acting Injectable Antipsychotic Medications

• Which antipsychotics do you routinely use in practice?
• If you were able to create a new long-acting injectable antipsychotic medication, what characteristics would you want the product to have?
  • Administration Interval?
  • Injection site and volume?
  • Preparation technique?
  • Oral overlap?
  • Ease of initiation? Loading dose?
Abilify Asimtufii®

- Indications: Schizophrenia, Bipolar I Maintenance
- Delivery Vehicle: Aqueous suspension
- Half-Life: not calculated
- Tmax: 1 to 49 days
- Drug Interactions: same as oral; CYP2D6 Poor metabolizers, CYP3A4 inducers and inhibitors, CYP2D6 inhibitors

Abilify Asimtufii® Dosing

• Every 56 days
• Oral overlap: oral medication required for 14 consecutive days

<table>
<thead>
<tr>
<th>Oral Dose</th>
<th>Abilify Maintena® Dose</th>
<th>Abilify Asimtufii® Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>15 mg aripiprazole</td>
<td>300 mg aripiprazole monohydrate</td>
<td>720 mg</td>
</tr>
<tr>
<td>20 mg aripiprazole</td>
<td>400 mg aripiprazole monohydrate</td>
<td>960 mg</td>
</tr>
</tbody>
</table>


## Abilify Asimtufii® Missed Doses

<table>
<thead>
<tr>
<th>Time Frame</th>
<th>Dosing Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;8 weeks and &lt; 14 weeks:</td>
<td>Administer the next dose as soon as possible</td>
</tr>
<tr>
<td>&gt;14 weeks:</td>
<td>Restart concomitant oral aripiprazole for 14 days with the next administered injection</td>
</tr>
</tbody>
</table>

Preparation and Administration

- Pre-filled syringe
- Gluteal IM injection
- No refrigeration required
- Use only needles and syringes provided within the kit
- Tap syringe at least 10 times on hand
- Shake the syringe vigorously for at least 10 seconds

Perseris®

• New injection site:
  • Subcutaneous in abdomen
  • Subcutaneous in back of upper arm
Rykindo®

• Delivery Vehicle: Microspheres

• Half-Life: 3-6 days

• Tmax: 14-17 days

• Drug Interactions: CYP3A4 Inducers, CYP2D6 Inhibitors

Rykindo® Dosing

- Every 14 days
- Oral overlap: 7 days of oral risperidone
- No current guidelines on dosing conversions

Rykindo® Missed Doses

- Patient should receive the next dose as soon as possible and supplement with oral risperidone as needed
Preparation and Administration

• Reconstitution and refrigeration required
• Gluteal IM injection

Uzedy™

- Delivery Vehicle: Aqueous Suspension
- Half-Life: 14-22 days
- Tmax: 8-14 days
- Drug Interactions: CYP3A4 Inducers, CYP2D6 Inhibitors

**Uzedy™ Dosing**

- Every 28 or 56 days
- Oral overlap: Not required

<table>
<thead>
<tr>
<th>Oral Dose</th>
<th>LAI Dose- Every 28 days</th>
<th>LAI Dose- Every 56 days</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 mg risperidone daily</td>
<td>50 mg</td>
<td>100 mg</td>
</tr>
<tr>
<td>3 mg risperidone daily</td>
<td>75 mg</td>
<td>150 mg</td>
</tr>
<tr>
<td>4 mg risperidone daily</td>
<td>100 mg</td>
<td>200 mg</td>
</tr>
<tr>
<td>5 mg risperidone daily</td>
<td>125 mg</td>
<td>250 mg</td>
</tr>
</tbody>
</table>

Uzedy™ Missed Doses

- Patient should receive the next dose as soon as possible
Preparation and Administration

- Requires reconstitution and refrigeration (may store for up to 90 days in its unopened original packaging at room temperature)
- Abdomen or upper arm injection; subcutaneously
- Flick syringe forcefully three times to move the bubble to the cap
- Pinch skin, inject needle, unpinch skin, push medication, leave needle in skin for 3 seconds, remove needle

SMI Adviser LAI Center of Excellence

• Clinical Tips
• Educational Webinars
• VF Recordings
• https://smiadviser.org/about/lai

Welcome to the Long-Acting Injectable (LAI) Center of Excellence (COE)

SMI Adviser created the LAI COE to promote the safe and effective use of LAIs. The ultimate goal of this effort is to improve the lives of individuals who have schizophrenia, schizoaffective, and bipolar disorders. The LAI COE provides clinicians with training opportunities, technical assistance, and vetted resources. These include:

• Live and on-demand webinars
• Virtual Learning Collaboratives
• Virtual Forums
• Email listserv
• On-demand consultations
• Intensive consultation to sites or communities
• Clinical tips and resources

The LAI COE is led by SMI Nursing Expert, Donna Rollin, PhD, APRN, SMI Adviser Physician Expert, Robert Cotes, MD, and SMI Adviser content partner, National Association of State Mental Health Program Directors (NASMHPD), and supported by members of the LAI Workgroup.

For individual and family resources on using long-acting injectables, visit the individual and family Knowledge Base.
FEEDBACK
Please help us improve the Clozapine & LAI Virtual Forum by completing this survey: http://smiadviser.org/forumfeedback

Pre-submit Cases
www.smiadviser.org/vfcases

UPCOMING VIRTUAL FORUM
8/2/23 @4:00-4:45pm ET
Clozapine (topic TBD)

For additional questions and resources – join the Clozapine and LAI Centers of Excellence Exchange Community
- www.smiadviser.org/cloz_lai_signup